Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11707457 IRAK degraders and uses thereof

Patent 11707457 was granted and assigned to Kymera Therapeutics on July, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

Kymera Therapeutics

0

Current Assignee

Kymera Therapeutics

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Date of Patent

July 25, 2023

0

Patent Application Number

180453940

Date Filed

October 10, 2022

0

Patent Citations

US Patent 7402325 Supercritical carbon dioxide extract of pharmacologically active components from

0

US Patent 7449458 Prodrugs of 2,4-pyrimidinediamine compounds and their uses

0

US Patent 7501496 Anti-OX40L antibodies

0

US Patent 7514444 Inhibitors of bruton's tyrosine kinase

0

US Patent 7528143 Bi-aryl meta-pyrimidine inhibitors of kinases

0

US Patent 7557210 2,4-pyrimidinediamine compounds and their uses

0

US Patent 7598257 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors

0

US Patent 7622496 Modified lysine-mimetic compounds

0

...

Patent Citations Received

US Patent 12091411 IRAK degraders and uses thereof

0

Patent Primary Examiner

Zinna Northington Davis

0

The present invention provides compounds, compositions thereof, and methods of using the same.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11707457 IRAK degraders and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool